Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study.
Zhang B, Liu H, Shi C, Gao Z, Zhong R, Gu A, Chu T, Wang H, Xiong L, Zhang W, Zhang X, Yan B, Teng J, Wang W, Bai H, Qiao R, Cheng L, Kuang Y, Zhao R, Zhong H, Han B.
Zhang B, et al. Among authors: xiong l.
BMC Cancer. 2024 Jun 11;24(1):715. doi: 10.1186/s12885-024-12479-0.
BMC Cancer. 2024.
PMID: 38862908
Clinical Trial.